Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany · Delayed Price · Currency is EUR 352.85
-6.20 (-1.73%)
Oct 10, 2025, 5:35 PM CET
Vertex Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Net Income | 3,638 | -535.6 | 3,620 | 3,322 | 2,342 | 2,712 | Upgrade |
Depreciation & Amortization | 199.8 | 207.2 | 181.3 | 148.3 | 125.6 | 109.5 | Upgrade |
Stock-Based Compensation | 685.8 | 698.5 | 581.2 | 491.3 | 441.4 | 429.5 | Upgrade |
Other Adjustments | -251.7 | -347.9 | -579.1 | -172.5 | -160.4 | 57.2 | Upgrade |
Change in Receivables | -170.8 | -99.3 | -84.1 | -358.6 | -274.7 | -223.4 | Upgrade |
Changes in Inventories | -645.7 | -517.3 | -322.9 | -136.4 | -92.8 | -132 | Upgrade |
Changes in Accounts Payable | 108.3 | 49.5 | 48.7 | 120.8 | 31.9 | 51.3 | Upgrade |
Changes in Accrued Expenses | 65.2 | 212.9 | 429.4 | 542.5 | 305.4 | 122.2 | Upgrade |
Changes in Other Operating Activities | -160.6 | -160.6 | -336.8 | 172.5 | -75 | 127.5 | Upgrade |
Operating Cash Flow | 3,846 | -492.6 | 3,537 | 4,130 | 2,644 | 3,254 | Upgrade |
Operating Cash Flow Growth | - | - | -14.35% | 56.23% | -18.75% | 107.32% | Upgrade |
Capital Expenditures | -346.7 | -297.7 | -200.4 | -204.7 | -235 | -259.8 | Upgrade |
Purchases of Intangible Assets | - | -187.7 | -58 | - | - | - | Upgrade |
Purchases of Investments | -7,364 | -7,696 | -3,787 | -988.6 | -605.2 | -450.7 | Upgrade |
Proceeds from Sale of Investments | 6,049 | 4,466 | 934.2 | 920 | 499.3 | 809.9 | Upgrade |
Payments for Business Acquisitions | - | -54 | -31 | -47.8 | - | - | Upgrade |
Other Investing Activities | 5.4 | - | - | - | - | - | Upgrade |
Investing Cash Flow | -1,710 | -3,770 | -3,142 | -321.1 | -340.9 | 99.4 | Upgrade |
Long-Term Debt Issued | - | - | - | - | 28.3 | 13.3 | Upgrade |
Long-Term Debt Repaid | -9.3 | -33.6 | -44.9 | -85.5 | -47 | -42.3 | Upgrade |
Net Long-Term Debt Issued (Repaid) | -9.3 | -33.6 | -44.9 | -85.5 | -18.7 | -29 | Upgrade |
Issuance of Common Stock | 108.5 | 114.6 | 134.6 | 186.3 | 102 | 264.9 | Upgrade |
Repurchase of Common Stock | -1,911 | -1,582 | -653.7 | -172 | -1,561 | -739.4 | Upgrade |
Net Common Stock Issued (Repurchased) | -1,802 | -1,468 | -519.1 | 14.3 | -1,459 | -474.5 | Upgrade |
Other Financing Activities | 3.3 | 6.2 | 1.8 | 3.5 | - | -1.8 | Upgrade |
Financing Cash Flow | -1,808 | -1,495 | -562.2 | -67.7 | -1,478 | -505.3 | Upgrade |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 63.2 | -42.6 | 26.9 | -29.2 | -13.4 | 20.6 | Upgrade |
Net Cash Flow | 391 | -5,800 | -139.7 | 3,712 | 811.2 | 2,868 | Upgrade |
Beginning Cash & Cash Equivalents | 4,591 | 10,372 | 10,512 | 6,800 | 5,989 | 3,121 | Upgrade |
Ending Cash & Cash Equivalents | 4,982 | 4,572 | 10,372 | 10,512 | 6,800 | 5,989 | Upgrade |
Free Cash Flow | 3,500 | -790.3 | 3,337 | 3,925 | 2,409 | 2,994 | Upgrade |
Free Cash Flow Growth | - | - | -14.99% | 62.97% | -19.55% | 100.39% | Upgrade |
FCF Margin | 30.73% | -7.17% | 33.81% | 43.95% | 31.80% | 48.24% | Upgrade |
Free Cash Flow Per Share | 13.50 | -3.06 | 12.81 | 15.15 | 9.27 | 11.37 | Upgrade |
Levered Free Cash Flow | 2,849 | -1,075 | 3,374 | 3,879 | 2,384 | 2,701 | Upgrade |
Unlevered Free Cash Flow | 2,483 | -4.02 | 2,966 | 4,024 | 2,447 | 2,504 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.